Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1124425.RAPcQXHlJUPpa2d6sLP-iJ0iUiHkNN4_hAA2y3KVC5vyA130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1124425.RAPcQXHlJUPpa2d6sLP-iJ0iUiHkNN4_hAA2y3KVC5vyA130_assertion type Assertion NP1124425.RAPcQXHlJUPpa2d6sLP-iJ0iUiHkNN4_hAA2y3KVC5vyA130_head.
- NP1124425.RAPcQXHlJUPpa2d6sLP-iJ0iUiHkNN4_hAA2y3KVC5vyA130_assertion description "[Genome-wide gene expression profiling by MACE (Massive Analysis of cDNA Ends) identified 80 genes to be differentially expressed between HD patients and controls, which could be linked to cardiovascular disease (e.g., KLF6, DUSP6, KLF4), to infection / immune disease (e.g., ZFP36, SOCS3, JUND), and to distinct proatherogenic pathways such as the Toll-like receptor signaling pathway (e.g., IL1B, MYD88, TICAM2), the MAPK signaling pathway (e.g., DUSP1, FOS, HSPA1A), and the chemokine signaling pathway (e.g., RHOA, PAK1, CXCL5).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1124425.RAPcQXHlJUPpa2d6sLP-iJ0iUiHkNN4_hAA2y3KVC5vyA130_provenance.
- NP1124425.RAPcQXHlJUPpa2d6sLP-iJ0iUiHkNN4_hAA2y3KVC5vyA130_assertion evidence source_evidence_literature NP1124425.RAPcQXHlJUPpa2d6sLP-iJ0iUiHkNN4_hAA2y3KVC5vyA130_provenance.
- NP1124425.RAPcQXHlJUPpa2d6sLP-iJ0iUiHkNN4_hAA2y3KVC5vyA130_assertion SIO_000772 24184689 NP1124425.RAPcQXHlJUPpa2d6sLP-iJ0iUiHkNN4_hAA2y3KVC5vyA130_provenance.
- NP1124425.RAPcQXHlJUPpa2d6sLP-iJ0iUiHkNN4_hAA2y3KVC5vyA130_assertion wasDerivedFrom befree-2016 NP1124425.RAPcQXHlJUPpa2d6sLP-iJ0iUiHkNN4_hAA2y3KVC5vyA130_provenance.
- NP1124425.RAPcQXHlJUPpa2d6sLP-iJ0iUiHkNN4_hAA2y3KVC5vyA130_assertion wasGeneratedBy ECO_0000203 NP1124425.RAPcQXHlJUPpa2d6sLP-iJ0iUiHkNN4_hAA2y3KVC5vyA130_provenance.